Form 8-K - Current report:
SEC Accession No. 0001193125-24-247021
Filing Date
2024-10-30
Accepted
2024-10-30 07:44:52
Documents
15
Period of Report
2024-10-30
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d903458d8k.htm   iXBRL 8-K 26635
2 EX-99.1 d903458dex991.htm EX-99.1 98157
  Complete submission text file 0001193125-24-247021.txt   294322

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20241030.xsd EX-101.SCH 3265
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE itci-20241030_def.xml EX-101.DEF 13366
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20241030_lab.xml EX-101.LAB 21787
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20241030_pre.xml EX-101.PRE 14122
17 EXTRACTED XBRL INSTANCE DOCUMENT d903458d8k_htm.xml XML 5128
Mailing Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921
Business Address 135 ROUTE 202/206 SUITE 6 BEDMINSTER NJ 07921 (646) 440-9333
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

EIN.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 241407476
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)